YUHSpace

BROWSE

Export

Cited 12 times in

Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC

DC Field Value Language
dc.contributor.author김창곤-
dc.contributor.author임선민-
dc.contributor.author조병철-
dc.date.accessioned2022-05-09T16:56:05Z-
dc.date.available2022-05-09T16:56:05Z-
dc.date.issued2022-01-
dc.identifier.issn2159-8274-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/188288-
dc.description.abstractHER3 is ubiquitously expressed in EGFR-mutant non-small cell lung cancer (NSCLC) irrespective of resistant mechanisms to EGFR tyrosine kinase inhibitors, thus garnering attention as a valuable therapeutic target. In this issue of Cancer Discovery, Jänne and colleagues highlight early clinical data supporting patritumab deruxtecan as a potentially appreciable agent for previously treated EGFR-mutant NSCLC.See related article by Jänne et al., p. 74.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherAmerican Association for Cancer Research-
dc.relation.isPartOfCANCER DISCOVERY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAntibodies, Monoclonal, Humanized-
dc.subject.MESHCamptothecin / analogs & derivatives-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung* / drug therapy-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung* / genetics-
dc.subject.MESHErbB Receptors / genetics-
dc.subject.MESHHumans-
dc.subject.MESHLung Neoplasms* / drug therapy-
dc.subject.MESHLung Neoplasms* / genetics-
dc.subject.MESHProtein Kinase Inhibitors / therapeutic use-
dc.titlePatritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorSun Min Lim-
dc.contributor.googleauthorChang Gon Kim-
dc.contributor.googleauthorJii Bum Lee-
dc.contributor.googleauthorByoung Chul Cho-
dc.identifier.doi10.1158/2159-8290.CD-21-1429-
dc.contributor.localIdA05991-
dc.contributor.localIdA03369-
dc.contributor.localIdA03822-
dc.relation.journalcodeJ03328-
dc.identifier.eissn2159-8290-
dc.identifier.pmid35022206-
dc.identifier.urlhttps://aacrjournals.org/cancerdiscovery/article/12/1/16/675614/Patritumab-Deruxtecan-Paving-the-Way-for-EGFR-TKI-
dc.contributor.alternativeNameKim, Chang Gon-
dc.contributor.affiliatedAuthor김창곤-
dc.contributor.affiliatedAuthor임선민-
dc.contributor.affiliatedAuthor조병철-
dc.citation.volume12-
dc.citation.number1-
dc.citation.startPage16-
dc.citation.endPage19-
dc.identifier.bibliographicCitationCANCER DISCOVERY, Vol.12(1) : 16-19, 2022-01-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Show simple item record

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

  • License
    sherpa_romeo
    sherpa_juliet

OAK

DSpace Software Copyright © 2002-2017 Duraspace Yonsei University Medical Library All right Reserves. / TEL:02-2228-2915 /
YUHSpace는 국립중앙도서관 OAK 보급사업으로 구축되었습니다.

Browse

Links